|
|
Jul 15, 2024 –
Trofinetide approved for children and adults with Rett syndrome (RTT): A therapeutics bulletin of the American College of Medical Genetics and Genomics (ACMG)
|
May 30, 2024 –
Consideration of disease penetrance in the selection of secondary findings gene-disease pairs: A policy statement of the American College of Medical Genetics and Genomics (ACMG)
|
May 30, 2024 –
Laboratory testing for preconception/prenatal carrier screening: A technical standard of the American College of Medical Genetics and Genomics (ACMG)
|
Nov 27, 2023 –
Mucopolysaccharidosis Type 1 (MPS 1) Newborn Screening Algorithm
|
Nov 27, 2023 –
Mucopolysaccharidosis Type 1 (MPS 1) Newborn Screening ACT Sheet
|
Nov 27, 2023 –
X-linked Adrenoleukodystrophy (X-ALD) Newborn Screening Algorithm
|
Nov 15, 2023 –
Elivaldogene autotemcel approved for treatment of cerebral adrenoleukodystrophy (CALD) in males: A therapeutics bulletin of the American College of Medical Genetics and Genomics (ACMG)
|
Nov 1, 2023 –
Omaveloxolone approved for patients aged 16 years and older with Friedreich ataxia (FRDA): A therapeutics bulletin of the American College of Medical Genetics and Genomics (ACMG)
|
Oct 24, 2023 –
ACMG in Action October 2023 Ezine
|